Furthermore, these could predict enhanced sensitivity to immune checkpoint blockade and poly ADP ribose polymerase (PARP) inhibitors, confirming SLAMF3 as an attractive immunotherapeutic target in ovarian cancer (61). Here, LY9 is linked to ovarian carcinoma.